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ABSTRACT  
The high incidence of Campylobacter jejuni-associated diarrhea, increase in the frequency of 
drug resistance in clinical isolates, and the recent association of C. jejuni infections and Guillain-
Barré syndrome has heightened the need to develop effective anti-Campylobacter vaccines. Due 
to the risk of auto-immunity, vaccination using inactivated whole-cells or attenuated cells cannot 
be considered. Subunit vaccines however are a viable alternative and have been shown to be 
effective against similar pathogens. The main goal of this research is to test efficacy of the 
catalase A (KatA) protein as vaccine candidate against this pathogen. It was determined that 
KatA co-fractionates with both the soluble and insoluble cell fractions and a balanced 
IgG1/IgG2a response could be produced against it following immunization in mice. It was 
demonstrated that these antibodies can mediate complement-specific bactericidal activity and 
reduced adhesion and invasion of human epithelial (Caco-2) cells by C. jejuni using established 
in vitro assays. 
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1.0 INTRODUCTION 
 
1.1 Campylobacter jejuni 
Diarrhoeal disease alone claims a toll of 5 million children per year (1).  Consequently, there is a 
tremendous need for vaccines to combat the enteric pathogens causing these illnesses. Common 
pathogens that cause infections in the gastrointestinal tract include Vibrio cholerae, Helicobacter 
pylori, Campylobacter jejuni, Salmonella spp., Clostridium difficile and enterotoxigenic 
Escherichia coli (2). All of these infections continue to represent a challenge for the development 
of vaccines that can either prevent the pathogen from colonizing, or penetrating the mucosal 
epithelium, and/or blocking the binding of microbial toxins or neutralizing them (2).  
Campylobacter jejuni is the most frequently reported causative agent of bacterial gastroenteritis 
in humans. Campylobacter jejuni cells are spirally curved Gram-negative rods with tapering 
ends. They possess a flagellum at one, or both, ends thus possessing a high degree of motility 
(3). They have a small genome of approximately 1.6-1.7 megabase pairs (Mbp) of AT-rich DNA 
(70%) (4). Infection occurs most often as a result of contact with poultry and through 
consumption of contaminated meat products, notably poultry (5; 6), pork (7), and beef (8), as 
Campylobacter species exist as a commensal flora in many domestic animals (9). In addition, the 
consumption of contaminated drinking water (10) and raw milk (11) have also been linked to 
large outbreaks of campylobacteriosis. Infected individuals often present with a broad range of 
symptoms including abdominal pain, bloody diarrhea, and fever while a histological examination 
of intestinal tissues reveals crypt abscesses, ulcerations, and elevated numbers of immune cells in 
the colon (12). Bacteraemia is detected in less than 1% of patients with Campylobacter enteritis, 
and occurs most often in patients with a severely compromised immune system (13; 14; 15). 
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Although the vast majority of infections are self-limiting, post-infectious complications include 
inflammatory bowel disease (IBD) (16), reactive arthritis (17), Miller-Fisher-Syndrome (18) and 
Guillain-Barré syndrome (GBS) (19). Campylobacter jejuni is also reported to be the second 
most common bacterial cause of traveler’s diarrhea, after Vibrio cholerae, among visitors in 
endemic regions (20; 21) and is thought to be one of the leading causes of mortality for young 
children in the developing world (22). An estimated 2-10 million cases of campylobacteriosis 
occur each year in the United States (23). The total annual costs from infection, calculated from 
both medical and productivity loses, is thought to be up to 8 billion US dollars annually (24). 
Campylobacteriosis is often treated with antibiotics and shortens the duration of diarrheal disease 
experienced by a mean of 1.3 days (25).  Considerable antibiotic resistance has developed over 
the past decade, as a consequence to this over usage, to both fluoroquinolones (26) and 
macrolides (27) further necessitating the development of a prophylactic treatment.  
The development of a Campylobacter vaccine has been impeded by a fundamental safety 
concern due to the association of Campylobacteriosis with GBS. GBS is a neurologic disease 
characterized by ascending paralysis that can lead to respiratory muscle compromise and death 
(19). It is the most common cause of acute neuromuscular paralysis in the developed world (19). 
The US centers for Disease Control and Prevention have estimated the incidence of C. jejuni 
infection to be 1000 cases for every 100,000 individuals in the population per year (28). It has 
also been estimated that 1 of every 1058 cases of C. jejuni infection are followed by GBS 
although the risk of developing GBS is increased if the patient was colonized by strain O:19 
(19). Campylobacter jejuni lipopolysaccharides (LPS) and lipooligosaccharide (LOS) have been 
reported to be the causative triggers for GBS, as they resemble human gangliosides, and 
infection can trigger the generation of antibodies that attack the gangliosides on the myelin 
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sheath (29). Immunoglobulin G (IgG) antibodies to GQ1b and GT1a gangliosides are found in 
more than 90% of patients with this acute demyelinating disease (21). This finding has provided 
evidence to implicate these antibodies for damaging motor-nerve terminals in afflicted 
individuals (21). Because of this association, there are serious regulatory concerns regarding C. 
jejuni vaccine candidates (29). Researchers are now searching for novel antigens to replace a 
whole-cell vaccine strategy.  
The high prevalence of campylobacteriosis poses a significant health burden and validates the 
need for a vaccine against this pathogen. The current lack of understanding of Campylobacter 
jejuni’s pathogenesis is largely due to the absence of a suitable animal model to represent human 
infection (30; 31). The animal model most frequently used to study human pathogens is the 
mouse, but murine models of C. jejuni infection have the disadvantages of sporadic colonization, 
the absence of clinical signs of disease, and a lack of intestinal immunopathology (30). This 
phenomenon is due in part to the colonization resistance exhibited by adult mice (older than 2 
months) with a normal intestinal microflora (30). The colonization resistance against 
Campylobacter can be diminished by the administration of a quintuple antibiotic treatment 
(ampicillin, vancomycin, ciprofloxacin, imipenem and metronidazole) to generate gnotobiotic 
(GB) animals (32). These animals can be subsequently populated with typical human flora (hfa) 
while both GB, and hfa animals, display the characteristic inflammatory responses seen in 
human campylobacteriosis (33). Other models, using ferrets (34) or rhesus monkeys (35; 36), are 
believed to accurately mimic the human course of disease. Their applications, however, are 
limited by practicality as housing these species requires specialized personal and an extensive 
animal care facility (31). Other studies have utilized chickens (37; 38), a natural host of C. jejuni, 
although the generalizability to human campylobacteriosis is not well established (31).  
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1.1.1 Combating Reactive Oxygen Species (ROS) 
Campylobacter jejuni is a microaerophilic bacterium and is damaged by the normal atmospheric 
level of oxygen (O2) and requires O2 in the range of (2-10%) for optimal growth (39). During 
aerobic metabolism, Campylobacter is exposed to several reactive oxygen species (ROS) 
including superoxide radicals (O2.-), hydroxyl radicals (.OH), and hydrogen peroxide (H2O2) 
generated during the reduction of molecular oxygen (40). ROS species damage DNA and cause 
the peroxidation of lipids (40; 41). Campylobacter jejuni is also exposed to ROS produced by the 
host immune system, primarily by polymorphonuclear leukocytes (PMLs), whose oxidative burst 
is cytotoxic for bacteria (41).  C. jejuni, however, possess a number of proteins and enzymes that 
are thought to protect it against the damaging effects of oxidative stress (42). The roles of SodB 
(superoxide dismutase), KatA (catalase), AhpC (alkylhydroxyperoxidase), Cft (ferritin), and 
FdxA (ferredoxin) in oxidative stress defense mechanisms have been partially characterized (43).  
In C. jejuni, the oxidative stress defense mechanisms are regulated by the peroxide-sensing 
regulator Per-R (44). 
1.1.2 Epithelial Translocation 
In an immunologically naive host, C. jejuni colonizes the mucous linings of the small and large 
intestines. The flagellum is composed of two closely related proteins FlaA and FlaB. This 
flagellum, combined with the spiral shape of the bacterium, confers the advanced motility that 
allows Campylobacter to burrow deep into the mucous (45). Because of this remarkable 
adaptation, it had once been speculated that adhesion to the host epithelia was not necessary and 
the bacterium remained in the intestine by colonizing the mucous (46).  More recently, several 
adhesion proteins have been identified, notably CadF and FlpA, that permit binding to the 
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extracellular matrix by attaching to fibronectin (47; 48). In response to the host environment, C. 
jejuni begins the synthesis of Campylobacter-invasion antigens (Cia), which are exported from 
the bacterium’s flagellar type III secretion system (T3SS), to facilitated host invasion (49). 
Internalization of the bacteria requires host cell signalling as well as rearrangement of the host 
cell cytoskeleton (50; 51). There is evidence these bacteria may also cross the epithelia via a 
paracellular route through tight junctions (3). Intracellular C. jejuni are able to induce the 
loosening of connections between adjoining epithelial cells thus facilitating the translocating 
across the enterocytes of the intestinal barrier (52).  
It has been suggested that Campylobacter sp. preferentially associate with the microfold (M) 
cells, to facilitate their invasion (53). M cells are a component of the mucosal-associated 
lymphoid tissue (MALT), located in follicle-associated epithelium (FAE), and are designed for 
the sampling and inward transportation of luminal material (54). The host response to infection 
includes the expression of pro-inflammatory cytokines that are dependent on nuclear factor кβ 
(NF-кβ ) and mitogen-activated protein kinase (MAPK) signalling pathways resulting in the 
recruitment of neutrophils and macrophages to site of infection (55; 56). The resulting 
inflammation exacerbates local tissue damage resulting in a loss of epithelial integrity. The 
compromised tissue leaks fluid containing blood, proteins, and inflammatory cells into the lumen 
generating the characteristic bloodied diarrhea (45).  
The immune cells within the intestinal mucosa, such as dendritic cells (DCs) and other 
phacocytes, provide the primary defense against C. jejuni. DCs play an important role in 
attracting moncytes, macrophages, natural killer (NK) cells, and especially T cells during the 
initial stages of infection (57). PMLs, predominantly neutrophils, infiltrate the intestinal epithelia 
and readily phagocytise complement-opsonized C. jejuni and kill them efficiently following a 
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ROS burst (3). In contrast to phagocytosis by PMLs, opsonisation by antibody or complement is 
not required for efficient uptake by macrophages (58).  After host invasion, C. jejuni appear to be 
largely confined to membrane-bound vacuoles but have also been observed in the cytoplasm in 
vivo (59). The bacteria have been observed to quickly invade Hep-2 (originating from human 
laryngeal epidermoid carcinoma) and INT407 cells (human embryonic intestinal cell line) after a 
1-2 hour exposure in vitro (60). At this early stage, Konkel et al. (1991) observed no lysosomal 
host response and the bacteria still possessed spiral morphologies. At later stages, a strong 
lysosomal response was evident and lysosomes, containing endosomes, surrounded the bacteria. 
By this point of invasion, the bacteria have generally changed from their spiral morphology into 
a coccal form (61). In an in vivo invasion, there is a reduction in the number of viable bacteria 
after the first 6 hours with few viable cells remaining by 36 hours (61). There is little evidence 
for intracellular multiplication of C. jejuni although vacuoles containing multiple bacteria have 
been observed within INT407 cells (60).                
1.2 Acquired Immunity 
The primary principle of vaccination is to administer a killed or attenuated form of a pathogen, 
that does not itself cause disease, that will instruct the body how to produce an effective immune 
response for when the pathogen is encountered again (62). Long-term protection requires the 
persistence of antibodies induced by the vaccine and the generation of immune memory cells 
capable of a rapid, and productive, reactivation (63). The first exposure to an antigen, either by 
infection or vaccination, leads to the activation of naive B lymphocytes and their subsequent 
differentiation into antibody-secreting plasma cells and memory cells. A secondary immune 
response is elicited when the same antigen stimulates these memory cells leading to a more rapid 
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proliferation and differentiation and the production of a greater quantity of specific antibodies 
then produced in the primary response (62).  
Most prophylactic vaccines work by stimulating the production of high-affinity neutralizing 
antibodies (64). Therefore, effective vaccines against microorganisms must induce memory B 
cell formation and these events occur primarily through the activation T helper cells. Other 
antigen-specific T cells, including cytotoxic T cells, perform important effector functions, such 
as the targeted removal of host cells infected by intracellular pathogens and provide support for 
macrophages in their removal of extracellular pathogens (65). Whole-cell killed or live-
attenuated bacterial vaccines are often the first formulation considered as they elicit both the 
innate and adaptive immune responses as the true pathogen would (66). These vaccines, 
however, may not always be safe to use depending on the pathogen and the target population. 
Before examining current developments in C. jejuni vaccines, the mechanisms in the 
development of protective immunity will be reviewed. 
1.2.1 Antigen Recognition 
The innate immune system recognizes molecular structures that are characteristic specific to 
microbes. These elements are referred to as pathogen-associated molecular patterns (PAMPs) 
and are expressed differentially by different classes of microbes (e.g. Gram-negative bacteria, 
Gram-positive bacteria, viruses, fungi). Most host cell phenotypes express pathogen-recognition 
receptors (PRRs) constitutively although phagocytes and DCs contain the most numerous and 
diverse receptors (67). Toll-like receptors (TLRs) are integral membrane glycoproteins capable 
of recognizing a variety of microbial PAMPS. The cytoplasmic portion of the TLR is similar to 
that of interleukin (IL-1) receptor family, referred to as Toll/IL-receptor (TIR), and is responsible 
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for the initiation of intracellular signalling (68). TLRs contain leucine-rich repeats (LRRs) in the 
extracellular domain capable of recognizing PAMPS (69). The successful activation of TLRs by 
microbes initiates signal transduction pathways which induces dendritic cell maturation and 
cytokine production (67). After ligand binding, TLRs dimerize and undergo a conformational 
change permitting the recruitment of a TIR-domain-containing adaptor molecule. To date, the 
TLR family consists of 13 members; 9 of which are functional in humans (Table 1) (67). TLRs 
expressed on the plasma membrane can recognize PAMPs in the extracellular environment. They 
may also be expressed internally on the endosomal membrane and detect the features of 
prokaryotic DNA and RNA. C. jejuni primarily activates TLR2 and TLR4 while TLR4 
signalling is responsible for most of the inflammatory changes seen during infection (70; 71). In 
contrast, TLR2 signalling has a protective role and acts to promote mucosal integrity (72). 
Bacteria and fungi are sometimes able to exploit the TLR system to evade host immune 
responses. Certain pathogens have modified forms of the normal TLR ligands, such as flagellin 
from H. pylori and C. jejuni, that TLR5 cannot recognize (73). Many individuals infected with C. 
jejuni are asymptomatic carriers (74; 75) and TLR5 evasion may be critical for establishing this 
carrier state which facilitates the persistence of the bacteria within human populations (73). 
In addition to the membrane-bound TLRs described above, two major classes of PRRs are found 
in the cytoplasm. The first, NOD-like receptors (NLRs) are a family of over 20 different 
cytosolic proteins which bind PAMPs and recruit additional proteins to form signalling 
complexes and promote inflammation. NLRs, like TLRs, contain three domains: (1) a LRR 
domain involved in ligand recognition; (2) a central NOD domain acting as an ATP-dependent 
dimerization domain (NACHT); and (3) an N-terminal caspase recruitment effector domain (76). 
21 
 
Table 1. Mammalian Toll-like receptors, predominant cellular localization, and specificity. 
Toll-like 
receptor (TLR) 
Location Specificity 
1 Cell membrane Bacterial lipopeptides 
2 Cell membrane Bacterial lipopeptides and peptidoglycan 
3 Endosome dsRNA 
4 Cell membrane Lipopolysaccharide (LPS) 
5 Cell membrane Bacterial flagellin 
6 Cell membrane Bacterial lipopeptides 
7 Endosome ssRNA 
8 Endosome ssRNA 
9 Endosome CpG DNA 
  Adapted from Uematsu & Akira (2006) (68). 
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There are three NLR subfamilies categorized by the effector domain utilized to initiate 
signalling. The caspase-recruitment domain (CARD) subfamily has two members: NOD1 and 
NOD2 which respond to bacterial cell wall peptidoglycans. NOD1 recognizes PAMPs derived 
from Gram-negative bacteria while NOD2 recognizes muramyl dipeptide found in both Gram-
negative and Gram-positive bacteria (77). These peptides may arrive in the cytoplasm of the host 
cell most often released from intracellular bacteria. They may also be transported into the cell 
from an extracellular pathogen via type III and type IV bacteria secretion systems (62). These 
secretion systems are found in Gram-negative bacteria, such as Salmonella and C. jejuni, 
encoded within pathogenicity islands (78; 79). Consequently, NLR detection can occur by non-
phagocytising cells such as epithelial cells.  When a peptide binds the CARD effector domain, a 
conformational change occurs facilitating the formation of the NOD signalasome and subsequent 
activation of the transcription of inflammatory cytokines and chemokines important for the 
stimulation and recruitment of additional effector cells (78). NOD1 and NOD2 are important in 
the defense against bacterial pathogens in the gastrointestinal tract such as C.jejuni and H. pylori. 
The second subfamily contains 14 known members with a Pyrin effector domain (PYD), which 
is activated by the presence of microbial products such as flagellin, muramyl dipeptide, LPS and 
crystalline substances, such as aluminum hydroxide (62). Activation results in the assembly of 
the inflammasome complex that binds and activates the enzyme caspase-1 (80). Caspases are 
cysteine proteases that initiate cellular programs leading to inflammation (pro-inflammatory) or 
cell death (pro-apoptotic) (81). Caspase-1 cleaves and activates IL-1β, an important pro-
inflammatory mediator produced at sites of tissue injury to recruit other immune cells. (82).  
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1.2.2 Dendritic Cells  
Dendritic cells have been described as professional antigen-presenting cells and are the primary 
source of antigen transport into the lymphatic system (83).  Dendritic cells are strategically 
located at the common sites of entry of microbes to the epithelia of the skin, gastrointestinal, and 
respiratory tracts, and in lymphoid organs and provide the primary defense against 
enteropathogens (57). In addition, they link the innate and adaptive immune responses to 
microbial pathogens by producing, and responding to, inflammatory cytokines (84). Dendritic 
cells are key initiators of adaptive immunity and are distributed throughout the body in their 
immature form (85). They actively sample the environment in peripheral tissues by endocytosis 
and macropinocytosis (86).  Immature DCs are highly phagocytic, and upon encountering a 
PAMP, undergo a process of maturation resulting in the increased expression of major 
histocompatibility complex (MHC) molecules (87), costimulators (88), Th polarising cytokines 
(89), and migration to the lymph nodes to prime naive T-cells (90). 
DCs express high numbers of pathogen-recognition receptors (PRRs) and most members of the 
TLR family to facilitate pathogen recognition. Bacteria encountered are internalized, by receptor 
mediated endocytosis, into phagosomes. The phagosome will undergo maturation and fuse with 
both endosomes and lysosomes. These vesicular interactions deliver host molecules with 
antimicrobial properties including generators of toxic reactive oxygen species (discussed later), 
proteases, thiol reductases and proton pumps (91). The resulting peptides from the protease 
digestion associate with MHC-II molecules present within the phagosome (92). External signals 
direct the DC to regional draining lymph nodes and initiates antigen processing and presentation 
(93).   
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Dendritic cells activated by C. jejuni express high levels of MHC molecules with bound peptide 
and upregulate co-stimulatory molecules such as cluster of differentiation (CD) CD40, CD80, 
and CD86 (94). The C. jejuni infection of DCs initiates expression of NF-κB leading to 
production of IL-1β, IL-6, IL-8, IL-10, IL-12, interferon (IFN) gamma and tumour necrosis 
factor (TNF) alpha (95). In addition, DCs begin expressing a chemokine receptor CCR7 specific 
for two chemokines (CCL19 and CCL21) allowing for migration to the T cell zones of lymph 
nodes (90).  Naive T cells also express CCR7 and migrate to the same regions of the lymph 
nodes antigen bearing DCs are concentrated. The recognition of MHC class II by the T cell 
receptor (TCR), along with adequate co-stimulation, results in the clonal expansion and 
differentiation of naive CD4+ T cells into an effector subtype of helper T cells (Th) (96).  The Th 
cells that have been activated are induced to proliferate, express the CD40 ligand, secrete 
cytokines, and migrate towards B-cells in the follicle (62).  
Most antigens from tissue sites are transported to lymph nodes by afferent lymphatic vesicles 
that drain into the subscapular sinus of the nodes. Soluble antigens (smaller than 70 kDa) may 
reach the B cell zone through conduits that extend throughout the follicle and interact directly 
with B cells (62). Large antigens may be captured by macrophages, in the subscapular sinus, or 
by dendritic cells, in the medullary region, that actively filter particulate antigen (97). The 
antigen is then transported into follicles where it can activate B cells. In all cases, the antigen 
presented has not been processed by antigen presenting cells (APCs) and in an intact, naive 
conformation (62). B cell activation is initiated when an antigen binds the B cell receptor (BCR). 
Although protein antigens, being monovalent, typically do not provide strong enough signals to 
induce B cell proliferation and differentiation, they can activate B cells and initiate a number of 
events. Activation of the BCR by antigen initiates coordinated assembly of the signalosome and 
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triggers a variety of cellular response including modifications to gene expression, reorganization 
of the cytoskeleton, and internalization of the antigen (98). Following antigen endocytosis, it is 
processed inside endosomes and presented in complex with a MHC class II molecule (99). This 
peptide is then presented by the B cell to a helper T cell activated when recognized an identical 
peptide presented by a dendritic cell (Fig. 1). 
1.2.3 T helper cells 
The CD40 receptor is constitutively expressed on B cells and is crucial for the initiation of 
antibody class switching. The CD40 ligand is upregulated on activated T cells and recognizes the 
CD40 receptor and provides a signal necessary for B cell survival (100). This binding induces a 
conformational change initiating an enzyme cascade which terminates with the activation of 
transcription factors which stimulate B cell proliferation and increase secretion of IgG (101). In 
addition to CD40L on Th cells activating B cells, Th cells also secrete cytokines that contribute 
to B cell responses and control the class of antibody produced. This process is referred to as 
isotype switching and provides B cells with the capacity to produce antibodies that perform 
distinct effector functions in the defence against various infectious agents. 
INF-γ is the main inducer of the production of IgG2a, an essential opsonin and effective activator 
of complement mediated lysis (102). Viruses and many bacteria activate the Th1 subtype and 
initiate responses resulting in the enhancement of several cytotoxic mechanisms. Th1 cells 
produce the cytokine IFN-γ which promotes the activation of macrophage and results in 
increased killing of intracellular pathogens (103). This occurs through increased expression of 
macrophage receptors for IgG2a and antibody-dependent phagocytosis (102). IFN-γ is also 
believed to be a major component of delayed type hypersensitivity reactions (DTH) (104). IFN-γ 
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initiates the inflammatory reaction by attracting T cells which secrete cytokines to recruit 
monocytes and granulocytes to the site of infection (104). 
The IL-4 cytokine is produced by Th2 and leads to the production of high antibody IgG1 levels 
and IgE antibodies. In addition, Th2 cells produce IL-3, an activator of mucosal mast cell 
proliferation (102), and IL-5 a stimulator of eosinophils (105). Consequently, Th2 activation can 
lead to the activation of allergic responses which is considered an adverse event following 
vaccination. Th1 and Th2 cells have been found to cross-regulate each other with respect to IgG 
and IgE production (103); Th2 cytokines (IL-4 and IL-10) have been shown to inhibit 
proinflammatory cytokines from macrophages (IL-1 and INF-γ) while IFN-γ enhances 
macrophage activation (106). Th17 cells produce the cytokine IL-17 which can induce neutrophil 
rich inflammation. 
Several theories are believed to influence the Th1/Th2 phenotype generated. The PAMP 
hypothesis postulates that interaction of host PRRs with PAMPs is the most important factor 
(85). A second hypothesis, referred to as the cytokine milieu, proposes that the cytokines 
secreted by activated T-cells in microenvironment promote differentiation of Th cells (85). 
During the course of an actual C. jejuni infection, dendritic cells generate a cytokine milieu that 
promotes the expansion of Th1, Th17 and the Th1/Th17 double-positive T cells (107). This 
occurrence reflects the importance of the production IFN-γ, IL-22, and IL-17 in enabling 
functional immune responses against C. jejuni infection (107).  
1.2.4 Plasma Cells  
Some of the progeny of the B cells that proliferate in response to antigen and T cell simulation 
will become antibody-secreting plasma cells. Long-lived plasma cells are generated in T-
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dependant germinal center responses (Fig. 1). This process is dependent on the initiation of high 
levels of Blimp-1 and interferon regulatory factor 4 (IRF4) (108). T cells secrete the cytokines 
that promote Blimp-1 expression, including IL-2, IL-6, and IL-21, through activation of the 
STAT3 transcription factor (109). The plasma cells, generated in the germinal centers, acquire 
the ability to travel to the bone marrow or local mucosa-associated lymphoid tissues (MALT) 
through the expression of CXCR4 (110). A proportion of plasma cells will remain in the spleen, 
initially in close association with mature DCs and later dispersing into red pulp (100). The 
stromal cells in the bone marrow, and the DCs in the spleen, secrete two related cytokines, BAFF 
and APRIL (111). The binding of these cytokines to the plasma cell receptors allows the cell to 
survive for long periods, often as long as the lifespan of the host. Memory B cells also express 
the antiapoptotic protein Bcl-2 which contributes to the long lifespan of these cells (112). The 
bone marrow becomes the major site of antibody production approximately 2-3 weeks after 
encountering a T-cell dependent antigen (113). Plasma cells may continue to secrete antibodies 
for months or even years after the antigen is no longer present (113). These antibodies can 
provide immediate protection if the antigen is encountered again. It is estimated that almost half 
the antibody in the blood of a healthy adult is produced by long-lived plasma cells and is specific 
for antigens encountered in the past (62). The ability of antibodies to neutralize pathogens is 
dependent on high-affinity and high-avidity interactions. Antibodies are highly specific for 
antigens can distinguish between two linear protein determinants differing by only a single 
amino acid substitution (62). The B cells in the repertoire that express the most specific antigen 
receptors are primed for proliferation. Continued antigen exposure drives rounds of B cell 
receptor diversification, selection, and proliferation until receptors reach high affinity (known as  
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Figure 1. Helper T cell dependent activation of B cells in response to protein antigens. Adapted 
from Abbas, Lichtman, and Pillai, (2012) (62).  
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affinity maturation) (114). The result of this process is that B cells producing higher affinity 
antibodies are preferentially selected and become the dominant cells in the population (114). 
Antibodies are large molecules, consisting of paired heavy and light polypeptide chains. These 
form a variable (V) antigen-binding region (known as V H and V L for the heavy and light chains 
respectively), as well as a constant (C) region (115). Antibodies are classified as isotypes, 
depending the type of heavy chain they possess, as either IgA, IgG1-IgG4, IgD, IgE or IgM. 
Each isotype has a unique capacity to reach different sites of infection and to recruit different 
effector mechanisms (65).  CD4+ activated T cells in lymphoid tissue release cytokines which 
drive the class switch and differentiation of B cells (116). Although this is a very complex and 
dynamic process, the cytokines identified to direct isotype switching are listed in Table 2 
(below).  
IgG is the principal isotype in blood and extracellular fluid (117). IgG opsonises pathogens to 
facilitate engulfment by phagocytes and activates the complement system (discussed below). In 
contrast, IgA is a less potent opsonin and a weak activator of complement. IgA is the major 
isotype in mucosal secretions and functions on epithelial surfaces where complement are 
phagocytes are absent. Therefore, the function of IgA is thought to be as a neutralizing antibody 
(118). 
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Table 2. Class-Switch Recombination (CSR); cytokines which direct immunoglobulin isotypes. 
Ig Isotype Dominant cytokine 
IgA TGF- β (119; 120) 
IgG1 IL-4 (121; 122) 
IgG2a IFN- γ (121) 
IgE IL-4 (122) 
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1.2.5 Antibody Function 
The main function of antibodies is to neutralize and eliminate infectious microbes and microbial 
toxins. Antibodies produced in the lymph nodes, spleen, and bone marrow may enter the blood 
and circulate throughout the body. Humoral immunity in the gut is dominated by the production 
of secretory IgA (sIgA) and sIgM in the gut-associated lymphoid tissues (GALT) (1).  
There may be some contribution from serum-derived or locally produced monomeric IgA and 
IgG which can reach the mucosal surface rapidly by paracellular diffusion through the 
epithelium (123) and transported across the mucosal epithelium into the lumen (Fig. 2). 
Activated B cells that undergo isotype switching into IgA producing cells in the gut-associated 
lymphoid tissue (GALT) and mesenteric lymph node become resident plasma cells in the lamina 
propria. The sIgA antibodies secreted on to the mucosal surfaces in the intestine are essential for 
preventing bacterial infection by binding and neutralizing microbes (124). These antibodies are 
thought to inhibit adhesive reactions by interfering with the ability of the microbes to interact 
with cellular receptors by causing steric hindrance. In some cases allosteric effects may occur 
from the binding of even very few antibodies. Alternatively, their binding may induce a 
conformational change in microbial surface molecules preventing interactions with cellular 
receptors (62).  
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Figure 2. The production of high-affinity IgA antibodies against an antigen via a T cell 
dependent activation of B cells.  The resulting secretion of high-affinity IgA can result in the 
neutralization of enteric pathogens. Adapted from Abbas, Lichtman and Pillai (2012) (62). 
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1.3 Adjuvants  
Adjuvants are substances that can improve an antigen-induced immune response by protecting 
the antigen, modulating cytokine release, activating CD8+ cytotoxic lymphocytes (CTLs) 
responses, or delivering the antigen to target tissue (125). Purified antigens are not usually 
strongly immunogenic and most acellular vaccines require the addition of an adjuvant in order to 
be effective (126). They enhance vaccine effectiveness by stimulating the innate immune 
responses at the sites of antigen exposure. Many adjuvants in experimental use are microbial 
products, such as killed bacteria and LPS, which can engage cellular TLRs.  
Dendritic cells are principle mediators of responses to TLR agonists (127) and activation 
stimulates the migration of DCs to lymph nodes where T cells are located. Adjuvants are highly 
effective immune stimulators and as a result can cause damaging amounts of localized 
inflammation.  As a consequence, a tremendous amount of effort has been devoted to the 
development of safe and effective vaccine adjuvants in humans (128). LPS is a component of the 
cell wall of Gram-negative bacteria and it is a potent adjuvant and TLR4 activator (129). LPS, 
however, is too toxic for clinical applications as even the injection of a small amount of LPS can 
cause systemic inflammation (130). A derivative of LPS, monophosphoryl lipid A (MPL) has 
been shown to retain the immunostimulating capacity but with decreased toxicity (127). This 
adjuvant, a derivative from Salmonella minnesota, is widely used experimentally and has been 
also tested in human clinical trials (131). Alum, composed of aluminum salts, remains the gold 
standard vaccine adjuvant as has been used for over 80 years due to its role in clinical 
applications. Aluminum is thought to enhance the mucosal immune response by localizing 
antigenic material in the interstitial fluid and extending the duration of antigen presentation to 
immune cells (127). A deposit is formed at the site of injection causing localized tissue damage 
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and increasing recruitment of APCs and antigen phagocytosis (132). In addition, alum taken up 
by macrophages has been shown to increase the duration of their survival (133). Alum signals 
through NLR NOD-2 and, as a result, is an effective inducer of humoral immunity and Th2-
biased CD4+ T cell responses (134). Other experimentally used adjuvants include 
lipopolysaccharide-polyribonucleotide complexes, imiquimod, muramyl dipeptide and 
analogues, nonionic block copolymers, saponin immune stimulating complexes (ISCOMS), the 
oral mucosal adjuvant cholera enterotoxin (CT), and dehydroepiandrosterone (DHEA) (135). 
1.4 Campylobacter jejuni Vaccine Research  
At present, there is no commercial vaccine available against C. jejuni although some benefit 
from whole-cell vaccines has been established. Infection of adult volunteers with live C. jejuni 
milk-borne strain 81-176 by Black et al. (1988) demonstrated the development of jejunal fluid 
sIgA decreased the likelihood of illness at secondary exposure (136).  A second clinical 
challenge study was recently published by Tribble et al. (2010) (27) vaccinating people with the 
same strain. The rates of systemic and mucosal response were comparable to rates observed after 
a natural exposure to the pathogen (137). Individuals were challenged one-year later and 
demonstrated a greater magnitude of IgA and IgM serological responses, and more rapid 
anamnestic fecal IgA, than naive participants. Before the study began, the LOS of the strain was 
characterized to determine if molecular mimicry was possible and initial results came back 
negative (138). Unfortunately, following the study a genetic analysis of the LOS core revealed 
that mimicry was in fact possible (139). It was determined that the vaccination had in fact posed 
a risk to the participants although no incidents of GBS were reported (139). A new strain of C. 
jejuni CG8421 has recently been identified and does not possess a risk of GBS for humans (140).  
Healthy adult volunteers were challenged with this live strain, by Kirkpatrick et al. (2013), and 
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were rechallenged after three months (141). Immune responses were the most robust following 
the first exposure where seroconversion, a minimum four-fold increase in antibodies, was present 
in 67% of participants. IgA levels returned to baseline within three months and neither IgA or 
IgG achieved seroconversion at rechallenge. A two-fold or greater increase in IFN-γ was 
observed following the first challenge with levels falling close to baseline by three months. 
Unfortunately, participants experienced diarrheal disease clinically similar from that of the 
primary infection following the rechallenge. The lack of immunity provides further evidence that 
long-lived protection is unlikely after a single exposure to live whole-cell C. jejuni.   
1.4.1 Subunit Vaccine Strategies 
Although attenuated vaccines elicit long-lasting immunity, safety issues including the 
administration of potentially harmful bacterial components, and the potential for replication or 
reversion to a pathogenic form, are of concern as vaccines are normally administered to healthy 
individuals (142). In the case of C. jejuni, the risks of eliciting an auto-immune response prohibit 
a whole cell vaccination strategy. For this reason, the use of a subunit vaccine approach is often 
warranted in which only the microbial components required to produce an appropriate immune 
response are administered. Although subunit vaccines have many desirable qualities, their ability 
to stimulate potent immune responses is much weaker than traditional whole-cell preparations 
(143). 
Recent work involving conjugate vaccines has been published combining capsular 
polysaccharides (CPS) from C. jejuni with protein carrier. Monteiro et al. (2009) conjugated CPS 
with diphtheria toxin (DT) mutant CRM197 and subcutaneously injected the non-human primate 
Aoutus nancymaae (144). Post-immunization serum collection revealed significant increases in 
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IgG, and IgM, but no increase in IgA. The animals were later challenged with 6 × 1011 colony 
forming units (CFU) of C. jejuni and observed for symptoms of illness. They reported that no 
animals experienced diarrheal symptoms but necropsy revealed intestinal colonization by the 
bacteria.  Bertolo et al. (2013) produced similar antibody levels with their CPS conjugate, CPS 
and an un-named protein, but the functionality of the antibodies in preventing infection is yet to 
be tested (145).  The principle obstacle with these vaccine designs is the considerable structural 
variation of CPS between serogroups (146). This diversity makes the design of a CPS vaccine 
capable of providing a broad range of immunity quite challenging. Additional vaccines have also 
been targeted against C. jejuni flagellum due to the important role it plays in invasion. Lee et al. 
(1999) immunized mice with a recombinant FlaA protein fused to the maltose-binding protein 
(MBP) of Escherichia coli (147). Mice were immunized intranasally with and without the mutant 
E. coli heat-labile enterotoxin (LT). Their formulation was effective in eliciting antigen-specific 
serum IgG and responses were enhanced when LT was co-administered. Significant levels of 
sIgA were also detected in the intestine. Animals were challenged orally with between 8x108 – 8 
x1010 CFU and protection against colonization ranged from 71.4% to 100% depending on CFU 
concentration. Although this formulation appears to provide good levels of protection in the 
murine model, it may be problematic in humans as portions of the C. jejuni flagella are highly 
conserved with other bacterial flagellins and may generate immune responses against normal gut 
microflora (148). Baqar et al. (2008) attempted to circumvent this issue by targeting the secreted 
non-flagellar proteins that are associated with virulence. FlaC, FspA1, and FspA2 are secreted 
Cia proteins required for the invasion of intestinal epithelial cells (IECs) (149). Each protein was 
administered individually intranasally to mice and all three were confirmed to be immunogenic. 
FspA1 induced the highest levels of serum IgG and fecal IgA, and provided the greatest percent 
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protection (63.8%) against 3 x109 CFU when combined with LT. Although promising results, 
increased levels of protection are still desired and FspA1 is yet to demonstrate efficacy in higher 
animals. 
Other research has focused on vaccine development against a virulence determinant of C. jejuni; 
cytolethal distending toxin (CDT). Advances in proteomics have permitted the design of 
pentapeptides, the smallest determinant functions as an antigen (150), which contain domains 
against CDT while being absent from the human proteome (151). Although intelligent in design, 
this vaccine strategy for C. jejuni has not been tested in vivo.    
1.5 KatA (Catalase) Protein  
The role of the catalase protein of C. jejuni (KatA) was discussed briefly above. KatA is a 
homotetrameric protein approximately 55 kDa in size. The protein is considered a typical 
catalase family member as it lacks peroxidise activity. Catalase appears to be primarily a 
cytosolic protein, however, data from investigations using the related species Helicobacter 
pylori, has indicated that the protein may have a surface localization as well (152; 153; 154). 
Harris et al. (2002) demonstrated that H. pylori was resistant to high concentrations of hydrogen 
peroxide (100 mM) using an in vitro tolerance assay. They compared the survival of KatA-
deficient mutants and discovered these bacteria were unable to survive the harsh incubation 
(155). It was subsequently demonstrated in vivo that mice immunized with the KatA-deficient 
mutant cleared the infection significantly more than those immunized with the wild-type strain 
(156). Palyada et al. (2009) confirmed the necessity of the KatA protein for C. jejuni 
colonization in vivo (42). They examined the ability of the C. jejuni strain NCTC 11168 ΔkatA 
mutant to colonize the cecum of one-day old pathogen-free baby chickens. They determined that 
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mutants were not able to establish a colony (the number of mutants per gram of cecum was 
below detection limit) compared to the wild-type strain which had 2.0x107 CFU per gram of 
cecum. The katA gene has been sequenced and codes for 508 amino acids (157). It has been 
suggested to be a potential vaccine candidate for a variety of enteric bacteria that require the 
KatA protein for colonization (155). Although many bacteria express catalase, they do not 
necessarily share homology; C. jejuni KatA is only 56% homologous to KatA from Helicobacter 
species, but is 99% conserved with other sequenced C. jejuni strains (158). The conserved 
sequence identity between C. jejuni strains made KatA a prospective candidate for our research 
on C. jejuni vaccine development. It has not yet been determined if humans can generate 
antibodies against this protein and a primary goal of this thesis was to determine KatA potential 
for vaccine development.  
1.6 Rationale Behind the Project 
One of the major concerns about the development of a vaccine against C. jejuni revolves around 
inadvertently causing the autoimmune dysfunction, Guillain-Barré syndrome. As a consequence, 
more traditional vaccination strategies, such as using whole-killed or live attenuated bacteria, are 
not feasible in these circumstances. The best vaccination strategy is therefore to select a strongly 
antigenic epitope against C. jejuni and attempt to elicit a robust immune response against it. The 
catalase of C. jejuni (KatA) has been proposed to be a vaccine candidate against this enteric 
pathogen.  
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1.6.1 Aims 
1) To determine if KatA is associated with the bacterial cell membrane. 
2) To determine if KatA is a potent antigen suitable for vaccine development. 
3) To determine if the antibodies generated against KatA, following the vaccination, have 
bactericidal properties and/or prevent invasion and adhesion of C.  jejuni to human IECs. 
1.6.2 Hypothesis 
Catalase from Campylobacter jejuni will induce robust immune responses when administered in 
vivo. The antibodies produced will also be functional and will prevent C. jejuni from infecting 
immortalized human epithelial cells. The primary goal of this research was to validate KatA as a 
potential vaccine target and to further the development of a safe vaccine against 
campylobacteriosis. 
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2.0 MATERIALS AND METHODOLOGY 
2.1 Campylobacter jejuni Culture Conditions 
Frozen C. jejuni strain 11168 was obtained from NCTC (Salisbury, UK). Ten microlitres (µL) of 
the bacterial suspension was streaked on Mueller-Hinton (MH) (Difco, New Jersey, USA) agar 
plates and incubated for 24-48 hours  under microaerobic conditions (5% O2, 10% CO2, 85% N2) 
at 37°C in an Invivo2 500 Hypoxia Workstation (Ruskinn Technology Ltd, Pencoed, UK). A 
single colony was selected and inoculated in 25 mL MH broth medium and incubated for 24 
hours. A total of 25 uL of this broth culture was then transferred to 250 mL sterile MH broth 
medium and incubated as above until the desired cell density was achieved.  
2.2 Bacterial Growth Curve  
Following the initial 24-hour growth period, 1 mL of MH broth culture was removed and 
transferred to a disposable clear cuvette and the optical density (OD) was measured at 600 nm 
using a portable spectrophotometer (Cell Density Meter 40, Fisher Scientific). Prior to measuring 
the culture broth, the cell density meter was calibrated using sterile MH broth. The measurement 
was repeated at time(s) 0, 1, 2, 6, 10, 16, 24, 30, 48, 54, 72 hours. A second aliquot of 100 µL 
was removed and diluted serially in sterile PBS to achieve a final dilution of 10-3,10-4, and 10-5 at 
time 0-9 hours, 10-4, 10-5, and 10-6 from time 10-24 hours, and 10-5, 10-6 and 10-7 at time 24-72 
hours. A 22 µL aliquot of diluted bacteria was then transferred to 11 mL of warm MH agar 
(0.7% agar), mixed thoroughly, and poured on to a 25 mL MH agar plate (1.5% agarose). The 
plates were incubated for 48 hours under microaerobic conditions, as described above, and the 
number of colonies were counted.  The number of colonies at each time point was multiplied by 
the dilution factor to determine the population density as a function of OD. The growth pattern 
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was also plotted as a function of time and as a function of OD.  Protocol based on work 
described by Al Rashid (1998) (159). 
2.3 Determination of Protein Concentration 
Protein concentration in bacterial fractions, and purified antibodies, was determined using a 
Thermo-Scientific (Canada) microplate protein assay kit (Cat#23225) containing bicinchoninic 
acid as the detection reagent. Standards were prepared by diluting bovine serum albumin (BSA) 
to 100 µg/mL in 0.15M NaCl to create standards of 1000, 1500, 750, 500, 250, 125, 25 µg/mL 
and 0 µg/mL. The BCA working reagents were combined at a ratio 50 parts reagent A with 1 
part reagent B as per manufacturer’s instructions. 25 µL of each standard or sample was 
transferred into a microplate well followed by the addition of 200 µL of working reagent. The 
mixture was incubated at room temperature for 5 minute before the absorbance was read at 562 
nm in a microplate reader (Synergy H4 Hybrid Reader, Biotek). In this colorimetric assay, the 
standards are the point of comparison for the protein concentration in the samples. This protocol 
is a dye-binding assay in which a differential colour change occurs in relation to the 
concentration of protein. Sample OD was determined following subtraction of the OD of the 
blank (0 µg/mL). 
2.4 Measurement of Particle Size Distribution and Zeta Potential 
The protein size distribution was measured using dynamic light scattering at 25°C with a 
Zetasizer (Malvern Instruments, UK). Briefly, 5 µL of KatA protein suspension (50 mM Tris, 
0.2% SDS, 0.1% Tween 20) was diluted in 50 µL of ddH20 (1:11 dilution) and added to a quartz 
low-volume cuvette (Hellma Analytics, Germany). The intensity of the Helium-Neon laser 
(633nm) light scattered by the sample preparation (Phase analysis Light Scattering) was 
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measured to generate a particle-size distribution (PSD) profile. For the zeta potential 
measurement, 20 µl of sample was diluted in 980 µL of ddH20 and transferred to a disposable 
capillary cell (Malvern Instruments, Cat#DTS1070). Three sets of measurements, comprised of 
10 unique measurements each, were conducted. Data was analyzed using Zetasizer Software 
version 6.32 (Malvern Instruments). 
2.5 Campylobacter jejuni Fractionation to Determine KatA Localization 
One-hundred millilitres of C. jejuni strain 11168 were grown in a 250 mL flask to an OD600 of 
1.5-2.5. They were then concentrated by centrifugation for 5 minutes at 3500 RPM and 
resuspended in 2 mL PBS (pH 7.4). The cells were then lysed by sonication using 6 cycles of 
four 5-second bursts with a 1-minute time interval between where the solution was placed on ice. 
The cell extract was ultracentrifuged at 100,000 xg for 1-hour at 4°C to separate the soluble and 
insoluble fractions. The insoluble fraction (pellet) was resuspended in 1 mL PBS and transferred 
to a 1.5 mL microcentrifuge tube and spun at 10,000 xg for 10 minutes. The wash and 
centrifugation steps were repeated twice. The supernatant fraction was concentrated using 
Amicon 3 K (3000 kDa cut-off) tubes until a final volume of 1 mL was achieved. Protocol based 
on work described by Blaser et al. (1983) (160). 
2.6 Antigen Purification of KatA Antibodies  
The KatA polyclonal antibodies were further purified using KatA protein. Nitrocellulose paper 
(BioRad, Mississauga, Canada) was cut into 1 cm squares and placed in each well of a 24-well 
tissue culture plate (Sarstedt, Montreal, Canada). 14 µg of purified KatA protein from A. Stintzi 
(refer to Appendix II: collaborator methodologies) was then spotted on each square and allowed 
to air dry in the shortest time possible to limit oxidation. The membrane was then blocked with 
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300 µl of 5% skim milk (Bioshop, Toronto, Canada) in PBS. The plate was placed on a rocking 
platform for 1 hour at 25°C. The membrane was washed 3 times in PBS and probed with the 
polyclonal serum from immunized mice from A. Stinzi (refer to Appendix II: collaborator 
methodologies) diluted in 1:5 in PBS and incubated overnight at 4°C. Membranes were then 
washed again 3 times in PBS for 5-minutes each at room temperature. The bound antibodies 
were eluted by the addition of 150 µl 0.1 M glycine (BioShop) buffer pH 2.5. The eluate was 
then neutralized with 15 µl 1 M Tris-HCl pH 8.0. The final solution was stored at -20°C.  
2.7 Enzyme-Linked Immunosorbent Assay (ELISA) 
Immulon 2HB microtiter plates (Fisher Scientific, ON, CA) were coated overnight at 4ºC with 
recombinant KatA protein at 5.0 μg/ml in carbonate coating buffer (15 mM Na2CO3, 35 mM 
NaHCO3, pH 9.6) and 100 μl of the antigen/coating buffer mixture was added to each well of the 
plate. Plates were washed 6X with Tris-buffered saline (pH 7.4) containing 0.05% Tween 20 
(TBST). Diluted mouse serum samples were added to each plate at 100 μl/well and allowed to 
incubate at 4ºC overnight. Plates were washed again with TBST. Biotinylated goat-anti mouse 
IgG, IgG1 and IgG2a antibodies (Invitrogen, ON, CA) were diluted 1/10000 and then added to 
each plate at 100 μl/well and were subsequently incubated for 1 h at room temperature. Plates 
were washed and alkaline phosphatase conjugated with streptavidin (Cedarlane Laboratories, 
Hornby, ON, CA) was diluted 1/5000 and 100 μl was added in each well followed by another 1 h 
incubation at room temperature. Plates were washed 6X times in double distilled water (ddH2O). 
Di(Tris) p-nitrophenyl phosphate (PNPP) (Sigma) was diluted 1/100 in PNPP substrate buffer 
and 100 μl/well was added to each plate. The reaction was allowed to develop for 5-15 min, and 
optical density (OD) absorbance values at 405 nm in a Synergy H4 Microplate Reader (BioTek 
Instruments, VT, USA) were recorded. IgG ELISA results are reported as titers, which are the 
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reciprocal of the highest dilution that gave a positive OD reading. A positive titer was defined as 
an OD reading that was at least two times greater than the values for a negative sample. IgG1 
and IgG2a ELISA results were reported as OD readings to determine if there was a shift in the 
quality of the immune responses. Sera from naïve, unimmunized mice were used as negative 
controls.  
2.8 SDS-PAGE  
Samples were incubated with 2β-mercaptoethanol (Merck, Germany) for 10 minutes at 100°C 
then separated by 12.5% acrylamide SDS-PAGE at 90 mV for 1.5-2.5 hours. Gels were stained 
with G250 Blue Coomassie stain (BioRad). A BLUeye prestained molecular weight marker 
containing standard proteins (FroggaBio, North York, Canada) was used. The gel was 
photographed in FluorChem FC3 imager (ProteinSimple, USA) to capture the relative molecular 
sizes of the sample proteins.  
2.9 Western Blot  
Preparations were processed by electrophoresis (SDS-PAGE, acrylamide 12.5%), transferred to 
nitrocellulose using a semi-dry transfer method and incubated overnight on a rocking platform in 
blocking  buffer (5% skim milk in TBST) at 4°C. Blots were then incubated with the polyclonal 
antibody diluted in blocking buffer at room temperature for 1-2 hours. The primary antibodies 
used were as follows: (1) C. jejuni Kat A protein Westerns: polyclonal serum from rabbit against 
KatA protein provided by Dr. Alain Stintzi (University of Ottawa, ON, Canada) (diluted 1:5000); 
(2) purified high-affinity KatA antibodies (from above serum) (diluted 1:1000). After washing 3 
times with TBST for 10 minutes on the rocking platform, secondary antibodies were added and 
incubated for 1-2 hours at room temperature. The secondary antibody used was donkey anti-
45 
 
rabbit IgG-HRP linked whole antibodies (GE Healthcare, Cat#NA934) (diluted 1:10000).  The 
membrane was placed in an activated ECL Western blotting detection reagent (GE Healthcare, 
Cat#RPN2209/8/9) for one-minute prior to film exposure. Blots were exposed to Amersham 
ECL Hyperfilm (GE Healthcare) and developed in a medical film processor SRX-101A (Konica 
Minolta, Japan).  
2.10 Animals and Immunization 
All animal model experiments were conducted according to the Guidelines for the Care and Use 
of Laboratory Animals as indicated by the Canadian Council on Animal Care and was approved 
by the Animal Care Committee of Laurentian University.  Forty-eight female BALB/c mice were 
obtained from Charles River Laboratories (Sherbrooke, Quebec, Canada). The mice were divided 
into six (6) groups of 8 mice each. The mice were 3-4 weeks old when they arrived and were 
housed at the Laurentian University Animal Care Facility (Sudbury, Ontario, Canada) under 
diurnal lighting (7 A.M. to 7 P.M.). Four mice were housed in each disposable plastic cage 
(Innovive, USA) food and water were provided ad libitum. The mice received the following 
formulations (Table 3): (A) PBS, (B) KatA protein from A. Stintzi (refer to Appendix II: 
collaborator methodologies), (C) KatA protein and alum, (D) KatA protein and monophosphoryl 
lipid A (MPL), (E) KatA protein, alum, and MPL, and (F) 108 inactivated Campylobacter jejuni 
11168 cells. C. jejuni was inactivated by a combination of heat and formalin inactivation. Half of 
the cells were inactivated at 60°C for 60 min, while the other half were inactivated by the 
addition of 0.02M formalin and incubated at room temperature for 1-hour. Inactivation was 
verified when cells were streaked on MH agar plates and no growth was observed over 48-hours 
under microaerobic conditions. All formulations were in a final volume of 50 μl that was 
delivered intramuscularly. The amount of KatA, alum and MPL in each of their respective 
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formulations was 5 μg, 100 μg, and 5 μg, respectively. The amounts of each component in each 
formulation are outlined in Table 3. The formulations were prepared fresh one day before 
immunization. The mice were immunized three weeks apart for a total of three immunizations. 
Any signs of adverse reactions to the immunizations were monitored. Mice were bled prior to 
immunization and one week after each subsequent immunization by facial vein techniques. One 
week after the final immunization, a final bleed was conducted by cardiac blood draw. These 
procedures were performed by Dr. Nelson Eng and Dr. Nitin Bhardwarj (Advanced Medical 
Research Institute of Canada, Sudbury, Canada: 2012).  
  
47 
 
Table 3. Mouse subject immunization schedule and vaccine details.  
Group 
Vaccine Formulation 
(per dose) 
Route of Immunization 
(t = 0, 3, 6 weeks) 
A PBS IM* 
B 5 µg Kat A IM 
C 5 µg Kat A, 100 µg of alum IM 
D 5 µg Kat A, 5 µg MPL IM 
E 5 µg Kat A, 100 µg alum, 5 µg MPL IM 
F 108 inactivated/killed C. jejuni in PBS IM 
*IM = intramuscular injection 
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2.11 Bactericidal Assay 
Serum was pooled from the eight animals in each immunization group. Each group of sera was 
then incubated at 56°C for 30 minutes to inactivate endogenous mouse complement. 
Subsequently, 50 μL of de-complemented sera, diluted tenfold in PBS, was mixed with 25 μL of 
a C. jejuni (strain NCTC 11168) suspension containing 5 x 104 CFU/mL in a sterile 96-well flat 
bottom microtitre plate. The plate was incubated for 15 minutes under microaerobic conditions. 
Subsequently, 25 μL standard guinea pig complement (diluted 1/50 in PBS) was added and the 
plate was further incubated for one hour under the same conditions as above. One millilitre 
aliquots were then removed and diluted in molten MH agar (0.7% agar) and poured on top of 
MH agar (1.5% agar) plates. Plates were incubated at 37°C using the above conditions for 48 
hours and the colonies on each plate were counted. Bactericidal activity was calculated as a 
percentage reduction in viable bacteria relative to respective control plates where no serum was 
added in the formula [CFU (bacteria + complement) - CFU (bacteria + complement + serum)] / 
CFU (bacteria + complement). Plating was done in duplicate on three different occasions. In a 
separate experiment done once, mouse complement was also used to compare activity. 
2.12 Campylobacter jejuni Adherence and Invasion Assays 
C. jejuni strain NCTC 11168 was grown in MH media for 24-48 hours under the standard 
microaerophillic conditions (as previously described). The cells were centrifuged for 10 minutes 
at 120 x g and the pellet was re-suspended in a volume of Dulbeccos’s modified Eagle’s Medium 
supplemented with Fetal Bovine Serum (10%) and non-essential amino acids (1%) to provide a 
final OD reading of 0.1. Caco-2 cat#HTB-37 (ATCC, Manasses, VA) cells were seeded and 
grown to confluence (1.0 x 106) cells in 24-well tissue culture plates. Serum from the immunized 
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mice was diluted in PBS (1:10, 1:50; 1:100; 1:200) and incubated with the bacteria for 1 hour at 
37°C. The mixture was then incubated with the Caco-2 monolayer for 3 hours at 37°C and 5% 
CO2 atmosphere.  
2.12.1 Adherence Assay 
The cells were then gently washed three-times with pre-warmed PBS and lysed via a 15-minute 
incubation with 0.1% Triton X-100 (Cornell, Philadelphia, PA) to release adherent and 
intracellular bacteria. The number of viable bacteria released was assessed by plating a 50-fold 
dilution on MH agar. Percentages of adherent bacteria compared to the controls. First, the 
survival rate of bacteria without serum, and second, the survival rate of bacteria incubated with 
serum from mice immunized with PBS. Three independent assays were performed each done in 
duplicate.  
2.12.2 Invasion Assay 
The gentamycin protection assay used in this study was the same as that described by Louwen et 
al. (2008) (161) and applied by Habib et al. (2009) (162). Following the serum incubation with 
the Caco-2 monolayer (described above) the cells were incubated for another 2 h in 1 mL of 
DMEM containing gentamicin (480 µg mL-1) to kill any extracellular bacteria. Following the 
incubation, the monolayer was washed and lysed as above.  
2.13 Statistical Analysis 
All comparisons were made using a one-way ANOVA with a post-hoc Tukey’s multiple 
comparison test. Results were analyzed using Prism software version 5.0 (Graphpad, USA). 
Results were considered to be significant if p ≤ 0.05. 
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3.0 RESULTS 
3.1 Campylobacter jejuni Growth Curve 
Campylobacter jejuni strain 11168 produced a predictable and reproducible pattern of growth 
MH media under microaerophillic conditions, (5% O2, 10% CO2, 85% N2) and 37°C, over the 72 
hour observational period (Fig.3). The period of exponential growth was determined to be from 6 
to 36 hours following the commencement of the observational period (24 hours after broth was 
inoculated). The optical density (OD) of the broth translated reliably into a population density 
after the number of colony-forming units (CFUs) were counted. A linear function was applied to 
the region of exponential growth and was used to estimate the population of the broth based on 
the OD measured. 
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Figure 3. Bacterial growth of C. jejuni strain NCTC 11168 in MH medium under microaerobic 
conditions (5% O2, 10% CO2, 85% N2) monitored over 72 hours. Optical density (OD at 600 nm) 
as a function of growth time. Four unique experiments were performed. 
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3.1 KatA Antibody Specificity 
The purified IgG antibodies received from our collaborator (A. Stintzi; refer to Appendix II) 
were derived from a mouse immunization with the KatA protein. The serum collected from the 
mice immunized by N. Eng and N. Bhardwarj (2012) (Sudbury, ON) was polyclonal in nature 
and produced high cross-reactivity with the assortment of C. jejuni proteins in our Western blots 
(Fig. 4A). The technique used in this thesis for isolating high-affinity antibodies from polyclonal 
serum for a specific protein was derived from Blaser et al. (1983) (160). This technique 
produced a significant increase in KatA protein specificity. Even with the additional purification, 
some cross-reactivity with other bacterial proteins was still evident validating the need for a 
method to more accurately detect this protein (Fig. 4B). 
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A.  
 
B.  
 
Figure 4. Detection of KatA protein via Western blot with high affinity KatA antibodies 
and polyclonal IgG serum. Duplicate Western blots from SDS-PAGE gels blotted using: (A) 
Antibodies purified with IgG magnetic beads and (B) high affinity KatA antibodies following 
additional in-house purification. Lane 1 and 2: duplicates of pelleted fraction; Lane 3 and 4: 
duplicates of supernatant fractions; Lane 5: purified KatA. Thirty-minute exposure to high-
sensitivity film. 
               1            2                    3           4                     5 
               1            2                    3           4                     5 
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3.2 Localization of the KatA protein 
In order for a vaccine against C. jejuni to be effective, the antibodies generated would have to 
bind epitopes on the bacterial membrane and prevent colonization in the small intestine. Thus, 
KatA would need to translocate to the membrane from the cytoplasm for antigen-specific 
antibodies to bind. While evidence has shown that this occurs with KatA in H. pylori (152; 153; 
154), the present study investigated the possibility of a similar localization in C. jejuni. After 
sonication of C. jejuni, and separation of insoluble and soluble fractions by ultracentrifugation, 
the amount of protein in each fraction was assessed using a Bradford assay. It was determined 
that the soluble fraction contained 1.18 mg/mL of protein while the insoluble fraction had 1.14 
mg/mL. Western blotting indicated that KatA is present in both fractions, providing some 
evidence that KatA may transiently localize to the membrane (Fig. 4 and Fig. 5). This suggests 
that a vaccine using KatA to prevent colonization may be possible. The detected bands were 
confirmed to be C. jejuni KatA by mass spectrometry. 
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Figure 5. KatA is localized both in cytoplasmic and membrane fractions of Campylobacter 
jejuni. Polyclonal anti-KatA antibody was purified by antigen-affinity chromatography and was 
used to determine the presence of KatA in both supernatant and pelleted fractions of C. jejuni 
lysate. Lane 1: Purified KatA; Lane 2 and 3: duplicates of supernatant fractions; Lane 4 and 5: 
duplicates of pelleted fraction. The major band in lanes 2-5 were identified as KatA by mass 
spectrometry analysis. 15-minute exposure to high sensitivity film. 
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3.3 Physiochemical Evaluation of KatA 
The average particle size distribution (PSD) for the KatA protein received from A. Stintzi (refer 
to Appendix II: Collaborator methodologies) was determined to be 108.3 nm. Three distinct 
peaks were detected with 41.6% of particles at average diameter 6.67 nm, 29.7% at 286.9 nm, 
and 22.6% at 45.49 nm. The polydispersity index PI, a measure of the width of molecular weight 
distributions (MWD), was recorded at 0.40. The PI describes how diverse the PSD range is 
(PDI<0.1 is monodisperse PDI>0.1 is multimodal) (163). A score of 0.40 reflects the presence of 
multiple, distinct distributions with no overlap between them. The surface charge of the particle 
was -4.58 mV indicating only poor predicted stability at ambient temperatures. 
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Figure 6. Analysis of physical properties of the KatA protein at ambient temperature. (A) 
Particle size distribution (PSD) in diameter nanometers (d.nm.). (B) Average particle surface 
charge = -4.58 milli-Volts (mV).   
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3.4 Antigenicity of the KatA Protein 
The immunogenicity of KatA from C. jejuni (A. Stintzi) was evaluated following the 
intramuscular injection of BALB/c mice. Sera were collected from all mice one week post-3rd 
immunization (refer to Table 3: Immunization details), and was used for total IgG ELISA. Sera 
from mice immunized with KatA alone had mean anti-KatA IgG end point titers of 1.9x106 (Fig. 
7). Mean ELISA titers were comparable, 3.9x106 and 3.8x106 in mice immunized with KatA in 
conjunction with alum and MPL respectively (Fig. 7, p < 0.05 compared to the PBS group). 
Mice immunized with inactivated C. jejuni had mean end point ELISA titers of 2.5x105. The 
highest titers (5.6x106) were observed in sera from mice immunized with KatA and a 
combination of both adjuvants (alum and MPL) (Fig. 7), which was significant (p < 0.05) 
compared to titers induced by KatA alone, PBS, and killed bacteria. These results suggest that C. 
jejuni KatA is immunogenic, and humoral responses can be enhanced with the addition of 
adjuvants. 
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Figure 7. C. jejuni KatA is immunogenic and immune responses are enhanced with the 
addition of adjuvants. Total IgG in mouse serum one week after three intramuscular 
immunizations was enumerated for mice administered with PBS (negative control), KatA, 
KatA+alum, KatA+MPL, KatA+alum+MPL or inactivated C. jejuni. Values represent the mean 
endpoint titers within each group of mice (n = 8). Error bars shown represent the standard error 
within each mouse group. * p < 0.05.  
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3.5 Adjuvant Modulation of KatA-Specific Immune Responses 
One week post-3rd immunization, sera were collected from all mice and used for IgG isotype 
ELISA. Sera from mice immunized with KatA alone had primarily antibody mediated immune 
response as reflected by the increased level of Th2 response compared to that of Th1 (Fig. 8). 
Mice immunized with inactivated C. jejuni also had a Th2 bias suggestive of a predominant 
antibody mediated response (Fig. 8). Balanced Th1 and Th2 responses were observed in mice 
that received KatA in conjunction with both alum and MPL (Fig. 8).  
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Figure 8. The addition of alum or MPL to KatA induces a balanced IgG1/IgG2a ratio. 
Mouse serum was evaluated for IgG1 and IgG2a subtypes and measured by OD405 by KatA-
specific ELISA. OD measurements are indicated for each mouse (n=8) in the scatterplot, where 
the line in each group represents the mean OD and error bars are indicative of standard error. 
Serum was analyzed from mice that were immunized with (A) PBS, (B) KatA, (C) KatA+alum, 
(D) KatA+MPL, (E) KatA+alum+MPL or (F) inactivated C. jejuni.  
 
 
  
62 
 
3.6 KatA Antibody Bactericidal Activity 
To determine the functionality of the antibodies generated by mice induced by the formulations, 
a bactericidal assay was conducted to evaluate the ability of the antibodies to kill C. jejuni NCTC 
11168. When bactericidal assays were conducted with guinea pig complement, serum from mice 
immunized with KatA alone showed a reduction of 11.3 ± 2.9 (SEM)%, while a 13.6 ± 2.2% 
decrease in bacterial counts was observed in serum from mice immunized with KatA and both 
alum and MPL (Fig. 9). As a control, immune serum from mice immunized with inactivated 
bacteria reduced counts by 24.6 ± 3.5%, which was significantly different from the reduction 
shown by KatA-induced serum (Fig. 9, p < 0.1). Interestingly, using mouse complement, serum 
from mice immunized with KatA alone and KatA+alum+MPL showed a bacterial reduction of 
7.2% and 19.7% respectively (data not shown).  
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Figure 9. Bactericidal activity of KatA antibodies generated following an intramuscular 
immunization in mice. Bactericidal activity was conducted by counting the number of C. jejuni 
NCTC 11168 colony forming units (CFU) at t = 0 and t = 1 hours using guinea pig complement. 
Reduction in bacterial counts was expressed as a percentage normalized against the group of 
mice that was immunized with PBS. *p<0.1. Two unique experiments were conducted each with 
samples examined in triplicate. 
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3.7 Adhesion and Invasion Assays 
In addition to bactericidal activity, antibodies may also be considered functional if they prevent 
the attachment or invasion of C. jejuni to epithelial cells in the small intestine (62). Serum 
(diluted 1:10, 1:50, and 1:100) from mice that were immunized with PBS, inactivated whole 
bacteria, KatA alone, and KatA with alum and MPL were incubated with C. jejuni and then 
added to Caco-2 human epithelial cells in vitro. At the 1:10 dilution, when normalized against 
serum from mice immunized with PBS, there was a 54.4 ± 2.4% CFU decrease in adhesion of C. 
jejuni to Caco2 cells using serum raised against whole bacteria, 43.5 ± 1.3% with KatA and 
alum/MPL, and 36.6 ± 2.5% decrease in CFU in serum raised against KatA alone (Fig. 10A, p < 
0.05). A significant dose effect was observed (p<0.05) with the percent decrease in CFU 
diminishing in the assays using serum diluted at 1:50 (Fig. 10B) and 1:100 (data not shown). 
In the invasion assay, at 1:10 dilution, there were no significant differences between the percent 
CFU decrease using serum from mice immunized with whole cell bacteria (53.5 ± 3.1%), 
KatA/alum/MPL (42.7 ± 4.9%), and KatA alone (40.4 ± 2.4%); however, all three groups 
showed significant reduction in bacterial invasion relative to the PBS control. This result 
indicates that all three sera equally interfered with the ability of C. jejuni to invade Caco-2 cells 
(Fig. 10C, p > 0.05). The addition of alum/MPL to KatA did not further decrease the number of 
bacteria invading Caco-2 cells compared to antisera raised against KatA alone. There was no 
significant difference between groups when the sera was diluted to 1:50 (Fig. 10D) and 1:100 
(data not shown), but the percent CFU decreases across all groups were lower compared to the 
1:10 dilution. In both cases, these results suggest that antibodies from sera induced by KatA 
affect the ability of C. jejuni to colonize in vitro. 
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Figure 10. The effect of KatA antibodies in preventing the adhesion and invasion of C. 
jejuni to human epithelial cells (Caco-2) in vitro. Sera from mice immunized with KatA, 
KatA+Alum+MPL, or whole killed C. jejuni (WB) were diluted 1:10 (A) and 1:50 (B) and 
incubated with C. jejuni followed by addition to Caco-2 cells. Bacterial adherence (CFU counts) 
was enumerated following a 48-hour incubation under microaerobic conditions. A one-way 
ANOVA was performed with a Tukey’s multiple comparison test to assess for statistically 
significant differences. C. jejuni invasion using 1:10 (C) and 1:50 (D) serum dilutions was 
determined using a gentamicin protection assay. The percent decrease of bacterial invasion 
(CFU/plate) for mice immunized with KatA, KatA+Alum+MPL, or whole killed C. jejuni (WB) 
was  normalized relative to mice immunized with PBS. *p<0.05; ***p<0.0005. 
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4.0 DISCUSSION 
4.1 Campylobacter. jejuni Observation 
Despite the bacteria’s reported in vitro culture fragility (164), the bacteria were easily cultured in 
the lab under microaerophillic conditions. As the culture aged, an increasing number of coccoid 
shaped bacteria were observed. This corresponds to work by Beck et al. (1983) who discovered 
that the age of the culture might influence the phenotypic properties of C. jejuni. As the bacteria 
age, their morphology transforms from the typical spiral shaped appearance to a coccoid form. 
The coccoid form dominates in older cultures and is believed to represent a degenerate state 
produced by unfavourable growth conditions (165). The bacteria were examined using a light 
microscope (400x – 1000x) to confirm the absence of coccoid forms, before usage in in vitro 
assays, to simulate in vivo invasion as much as possible.  
4.2 KatA Protein Characterization 
Proteins are dynamic structures and often exist in a state of flux between the native and partially 
unfolded intermediates (62). The size of a protein is an important physical characteristic that 
provides useful information including the presence of monomers, dimers and trimers, changes in 
conformation, aggregation state, and denaturation (166). The PSD analysis revealed the presence 
of several distributions of protein sizes (Fig. 6A) in contrast to an expected singular distribution. 
Proteins that may be denatured, unfolded, and aggregated into clusters, is undesirable from the 
immunization perspective as the resulting antibodies generated will not be of high-affinity for the 
native form presented by the bacteria (62). Consequently, the state of the protein may have 
reduced the effectiveness of the immunization as many antibodies are conformation-dependent 
(166). 
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 Zeta potential is a measure of the magnitude of the electrostatic or charge repulsion/attraction 
between particles, and is one of the fundamental parameters known to affect stability (167). The 
greater the surface charge of a particle, the greater the force of repulsion between them smaller 
the probability of aggregation occurring (167). The zeta potential of KatA at physiological pH 
(≈7.0) was determined to be -4.58 mV. This indicates that under physiological conditions, the 
protein is near its isoelectric point (IEP); the pH of a protein solution at which the net charge or 
zeta potential of protein is zero (168).  Unfortunately, at the IEP of protein, its structure is more 
hydrophobic, more compact and less stable due to absence of inter-particle repulsive forces 
(169). This may explain the apparent lack of stability and presence of larger size particles found 
in the PSD analysis.  
4.3 Cellular Localization of the KatA Protein 
The technique utilized in this work to isolate high-affinity KatA antibodies from a polyclonal 
IgG sera produced a visible increase in KatA protein specificity. Even with the additional 
purification, some cross-reactivity with other bacterial proteins was still evident (Fig. 4B) 
validating the need for a method to more accurately detect this protein. Monoclonal antibodies 
(mAbs) are efficient analytic tools for detection, screening and characterization of biomolecules, 
and have wide application as diagnostics (62). mAbs have been successfully used to identify 
serotype specificity but none are commercially available for the KatA protein. The development 
of a mAb for KatA would allow for more accurate protein detection and quantification through 
densitometric analysis.   
Results from the bacterial fragmentation experiment indicated that KatA is present, in 
approximately equal amounts in both the soluble and insoluble partitions (Fig. 5). These findings 
provide some evidence that KatA may be able to induce the production of functional antibodies 
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that act on the bacterial surface but further investigation is warranted. In addition, the bacteria 
utilized in these experiments were not in their harsh host environment, but rather floating 
contently in their nutrient-rich broth. Other research has indicated that the expression of KatA is 
upregulated and transport to the surface occurs only after the bacteria have encountered a host 
(152). Consequently, this experiment does not reflect how KatA is presented when the infectious 
process is actually occurring. It may be of benefit to repeat the experiment using bacteria that 
have been primed for invasion by first having them encounter host cells. Following this priming, 
the KatA expression pattern will be more reflective of that in vivo and thus will provide more 
information concerning the localization of KatA during invasion.  
In these experiments, the localization of KatA to the membrane was not confirmed definitively. 
The separation procedure divided the cellular contents into soluble (cytoplamsic contents) and 
insoluble (inner and outer cell membranes). The presence of KatA detected in the insoluble 
fraction does not discern which membrane, or at what ratio, the protein is associated. 
Interestingly, two separate proteomic analyses by Jang et al. (2014) (170) and Elmi et al. (2012) 
(171) reported the identities of all proteins found within outer membrane vesicles (OMV) 
secreted by C. jejuni.  OMVs are nano-sized vesicles (10-500 nm) (172) secreted by Gram-
negative bacteria. They contain a sampling of outer membrane contents including LPS, OMPs, 
periplasmic proteins, virulence factors and occasionally cytoplasmic proteins (173). The 
presence of KatA was not reported in either analysis which does not support the idea that it has 
an outer-membrane localization. However, the bacteria used in these analyses were not activated 
by the presence of host cells thus the OMVs examined were not reflective of protein expression 
and localization that occurs during in vivo invasion.  
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The outstanding question of KatA localization could be resolved quickly if a monoclonal 
antibody was available. Monoclonal antibodies can be successfully conjugated to fluorochromes 
such as fluorescein, biotin, Texas Red, and phycobiliprotein (174). Conjugation of fluorescein 
isothiocyanate (FITC) to purified antibody is an extremely valuable technique for identifying 
surface molecules using either fluorescence microscopy or flow cytometry (174). Thus, 
fluorescent mAbs would highlight the presence of KatA at the cell surface under various 
conditions (i.e. unstimulated versus stimulated by epithelial cells). Alternatively, the outer 
membranes of C. jejuni could be extracted, as with other Gram-negative bacteria, using a mild 
detergent and separated using an SDS-PAGE in a similar fashion to that demonstrated by 
Acevedo et al. (2009) (175). The high-affinity KatA antibody preparation, used in the present 
study could be used to determine if the protein was absent. A positive result, however, could 
only be confirmed following protein band analysis using mass-spectroscopy due to antibody 
potential for cross-reaction. Again, the identification process would be simpler and more 
accurate if a mAb was available. 
4.4 Antigenicity of the KatA Protein 
The second major goal of this thesis was to determine if the KatA protein could stimulate 
antibody production. Large quantities of IgG were detected in serum one-week following the 
third IM vaccination of mice. As expected, the addition of adjuvants MPL and alum stimulated 
even higher titers of anti-KatA antibodies, especially when used in combination.  
The administration of the KatA protein produced a dominant IgG1 response as injected soluble 
antigen favours Th2 responses (176).  The administration of killed bacteria also produced a 
dominant IgG1 response as expected. The addition of MPL produced increased IgG2a as 
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expected through the predicted engagement of TLR4 (177). MPL has been shown to direct Th1 
responses and is currently the adjuvant used in Melacine®, a licensed cancer vaccine (178). 
Recently, the combination of L-tyrosine and MPL® enhanced murine antigen specific IgG2 
antibody responses without enhancing antigen specific IgE responses (179). For this reason, 
MPL is now being considered for use as an adjuvant in clinical allergy vaccinations (179). 
Therefore, the continued use of MPL in further C. jejuni vaccine development may be warranted 
to counter balance IgE levels, should it be elicited by the KatA protein.  
The addition of alum increased the levels of IgG2a which was an unexpected result as alum 
normally promotes a Th2 biased response (180). Finally, the trifecta of KatA, MPL, and Alum 
produced approximately equal amounts of IgG1 and IgG2a. While there are several theories that 
exist as to how alum functions as an adjuvant including acting as a depot, and  allowing extended 
contact with the antigen and the APC, there is another theory that suggests that alum is not 
actually driving Th2 differentiation but instead is suppressing Th1 responses (180). Brewer et al. 
(1996) observed that administration of an antigen with alum, in the absence of IL-4,  generated 
concomittant T cell responses resulting in the production of both IgG1 and IgG2a isotypes (181). 
Th2 responses normally occur when IL-4 stimulates transcription factor STAT6 which controls 
expression of the master Th2 regulatory transcription factor, GATA-3 (182). IL-2 has also been 
identified to play a critical role in this process throught the activation of STAT5 leading to 
transctiption of IL-4 (183). Th2 differentiation has also been proposed to proceed through an IL-
4 independent mechanisms when peptides are presented at low concentrations (184). TCR 
activation under these conditions stimulates increases in GATA3 mRNA and induces IL-2 
production activating STAT5 (185). The fact that  IL-4 knockout mice can still stimulate Th2 is 
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believed to be due to this signal pathway redundancy (136). Therefore,  IL-4 is not required 
under certain circumstances to initiate Th2 differentiation. 
The suppression of Th1 by alum would allow for the Th2 differentiation to occur uninterrupted 
as IFN-γ would not be able to suppress the expression of GATA3. In the present work, the KatA 
protein adsorbed to alum was able to induce concomittant KatA specific Th1/Th2 responses. 
This preliminary data suggests that KatA induces an IL-4 independent Th2 response which 
would allow for the alum to lead to unbiased T cell responses. Consequently, isotype switching 
to both IgG1 and IgG2a would occur as observed in our experimental results.  While we 
recognize that the immune system is complex, and multiple systems can influecen the reseponse, 
this work relies on the Th1/Th2 paradigm which does not take into account other T helper 
subtypes. 
The achievement of a balanced Th1/Th2 response is desirable for a C. jejuni vaccine as 
Campylobacter-specific IgA and IFN-γ are associated with resistance to clinical disease 
suggesting these components might be important markers of protective immunity (136; 186). 
Initially, it would be desirable to prevent infection through the secretion of high-affinity anti-
Campylobacter antibodies. If the first line fails, and infection occurs, then enhanced cell-
mediated immunity via macrophage would be desirable.  
4.5 Functional Antibody Assessments 
The antibodies produced in the immunization had some bactericidal properties. Our bactericidal 
assay demonstrated only partial killing of C. jejuni using serum from mice immunized with 
whole killed Campylobacter, KatA alone or KatA+alum+MPL. None of the immunized groups 
demonstrated a true bactericidal activity as industry standards require cell survival to be less than 
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50% (187). The killing of the bacteria in this assay is believed to occur through the activation of 
complement cascade (reviewed in appendix 1) and subsequent insertion of the MAC leading to 
cell lysis (188). Serum from the animals immunized with whole bacteria induced the greatest 
amount of cell death as to be expected. Parkhill et al. (2009) analyzed the genome and predicted 
that approximately 20 genes code for constitutively expressed OMPs (189).  Several of these 
proteins can be expected to be immunogenic and the other components of the cell surface, such 
as LOS and LPS have been determined to produce antibodies in mice. Therefore, following the 
IM administration, potentially dozens of antibodies were generated against the bacteria’s surface 
thus increasing the likelihood of complement assembly. 
Despite the advantages of the whole-killed bacteria administrations, the KatA immunization 
groups performed considerably well. The addition of adjuvants to the KatA protein did not 
significantly enhance bacterial killing. IgG1 is the IgG subtype with the highest affinity for 
complement proteins and is therefore the most critical for the activation of the classical pathway 
(62). The KatA protein alone generated high quantities of the IgG1 isotypes and the addition of 
MPL and Alum did not increase levels of IgG1 and enhanced IgG2a which has an extremely low 
affinity for complement (62). Thus, it makes sense for the KatA adjuvanted group to produce 
only slightly more bactericidal activity than the KatA protein alone. Interestingly, serum from 
the mice immunized with PBS displayed bactericidal activity suggesting that bacterial killing 
was also occurred due to alternative and lectin complement pathway activation. Consequently, 
data was normalized to subtract this baseline endogenous activity. This assay was not conducted 
as a simulation of a real invasion process as the bactericidal activity of serum is effective only 
against Gram-negative bacteria which have entered the bloodstream (190). Rates of bacteraemia 
are very low and detected in < 1% of patients with Campylobacter enteritis, occurring most often 
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in patients with a severely compromised immune system (15). These results do, however, 
provide evidence that the KatA antibodies generated are capable of binding to the bacterial 
surface.  
4.6 Adhesion and Invasion Assays 
It is not enough to report the production of antibodies; they must also be functional in order for 
an antigen to be useful in vaccine development (191). Most vaccines are validated using a 
challenge experiment in an animal model to determine vaccine efficacy (192). This is often done 
challenging the subject following the initial immunizations, by administering an elevated dose of 
the live pathogen, and examining whether the disease state occurs (192). Because of the lack of 
reliable animal models to simulate campylobacteriosis, cell culture models of bacteria with the 
epithelium are valuable for defining bacteria-host interactions. These models are used because 
they are thought to mimic the same bacteria-host interaction that occurs in the natural disease. 
The ability of C. jejuni to enter, survive, and replicate in mammalian cells has been widely 
studied using in vitro models (193; 59; 194; 195; 196; 197). Studies have shown that C. jejuni 
harvested from earlier phases of growth exhibit greater adherence to human epithelial cells than 
those from older colonies (>72 h) (60). Bacterial growth temperature is a second factor which 
influences adhesion to epithelial cells and adhesion was determined to be most efficient at 37°C 
(60).  Because of this, all of our experiments were conducted with bacterial colonies in the log 
phase of growth (36-48 hours post-inoculum) in a microaerobic chamber set to 37°C. Results 
from our data suggest that KatA antibodies can physically prevent C. jejuni from attaching and 
invading host epithelial cells as shown by the in vitro studies using Caco-2 cells.  Caco-2 cells 
were selected as they can partially differentiate in culture to produce microvilli, form tight 
junctions between cells, and express apical surface enzymes characteristic in in vivo enterocytes 
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(45). Confluent cultures, as used in the assay, exhibited the dome morphology characteristic of 
mature enterocytes indicating that the monolayer was functionally polarized (198). The polarity 
of IEC is important determinant of cell responses to microbes and essential for a realistic 
simulation of in vivo invasion (199). Interestingly, immunizing mice with KatA alone generated 
serum capable of decreasing the number of bacteria that could attach/invade Caco-2 cells. Mice 
immunized with whole bacteria, which included other potent immunopotentiators such as LPS, 
performed only marginally better than the serum from the animals immunized with KatA (Fig. 
10).  
It is important to note the limitations of the in vitro assays used in these experiments. First, the 
reported adhesion of C. jejuni with intestinal epithelial cells (IECs) is often reported to be less 
than 1% of the starting inoculum (200) (ours ranged from 0.01-0.1%).  This low level of 
adhesion does not correlate with the clinical presentation in humans (200). This phenomenon is 
likely due to atmospheric oxygen conditions required for the survival of the IECs. Although our 
assay incubations were performed under low oxygen conditions, there were several periods up to 
30 minutes in duration where the plates were under atmospheric conditions which may have been 
harmful to the bacteria. The relevance of the adhesion and invasion assays can be called into 
questions as during the course of a real C. jejuni host invasion, sIgA would be the most critical 
antibody to prevent adhesion. IgA levels were not evaluated in this experiment as they were not 
expected to be significant following an IM administration. The purpose of this investigation was 
to simply verify if KatA would be immunogenic following immunization. The next step in the 
course of investigation would be to administer the KatA protein mucosally, either orally or 
intranasally, and evaluate the levels of sIgA produced at mucosal sites. The adhesion and 
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invasion assays could be repeated in vitro but conducting a live challenge in the immunized 
animal would be the best way to evaluate protective immunity. 
If indeed KatA is not present at the cell surface, then it would appear that we have generated 
cross-reactive antibodies capable of effectively binding another surface protein. This in itself 
would be an important discovery as antibody binding to this protein(s) is effectively reducing the 
rates of adhesion and invasion. This is in fact possible as the western blot of fractionated bacteria 
revealed that, even with the high-affinity antibodies, three additional proteins were detected (Fig. 
4). These proteins were also sent for mass-spectroscopy and the results revealed that they were 
not the KatA protein.  
4.7 Conclusion 
The high prevalence of C. jejuni infections, increases in antibiotic resistance, and the incidence 
and severity of post-infectious syndromes validates the need for a prophylactic vaccine. The 
development of such a vaccine has been hindered by the unique structure of C. jejuni LOS and 
the potential for molecular mimicry to generate auto-immune disorders. Thus, the most 
promising strategies involve the development of subunit vaccines. The data in the present 
experiment provides some support the candidacy of the KatA protein as a vaccine antigen but 
many fundamental questions remain unanswered.  This is the first indication KatA from C. jejuni 
may be a useful vaccine antigen. Catalase is also believed highly conserved between 
Helicobacter sp., although such a comparison is yet to be reported for Campylobacter sp., the 
protein is fundamental for the pathogen invasion. Future studies will examine the efficacy of 
KatA in mucosal deliveries combined with potent mucosal antigens. Before any true conclusions 
can be drawn, KatA must demonstrate protective immunity against a live C. jejuni challenge. 
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This work increases the vaccine antigen knowledge base against C. jejuni and offers hope that a 
safe and effective vaccine can be produced. 
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APPENDIX 1: The Complement System 
The complement system is a humoral proteolytic cascade based defense mechanism and 
is a crucial component of the innate immune response against pathogens. It is comprised of over 
25 plasma proteins and cell surface receptors (201). Together, they function in concert to 
opsonise microbes, to promote the recruitment of phagocytes to the site of infection, and in some 
cases to directly kill the microbes via lysis (202). There are three main ways to activate the 
complement system: through antibodies (classical pathway), through large multimeric lectins 
(lectin pathway), and through a low-level inherent activation (alternative pathway) (Figure 3). 
All three pathways merge at the level of cleavage of the plasma protein C3 which leads to the 
formation of active fragments and the initiation of a proteolytic cascade involving other 
complement proteins (190). The classical pathway of complement activation can be initiated 
once an antibody has bound to the surface of a microbe. The plasma protein C1q binds to IgG 
and IgM but not IgA, IgD or IgE (203). C1q consists of 6 identical subunits with globular heads 
capable of binding the Fc region on Ig. Each C1q must simultaneously bind at least 2 Fc regions 
in order to become active. Thus, only multivalent antigens with multiple antibodies bound can 
activate complement.  C1q  lacks enzymatic activity but is associated with two serine protease 
proenzymes C1r and C1s (204). C1q will bind to the CH2 domain of IgG, or the CH3 domain of 
IgM, antibodies resulting in a conformational change leading to the autoactivation of C1r which 
cleaves and activates C1s (205). C4 is also cleaved by C1s into C4a and C4b exposing a binding 
site for C2. Upon binding, C2 is cleaved into C2a and C2b while C2a remains bound to C4 and 
functions to recruit and cleave C3 into C3a and C3b. C3b contains a highly reactive thioester 
domain that is exposed following clevage (206). The thioester domain can form covalent 
attachments, to the amino or hydroxyl groups of surface proteins or polysaccharides, but reaction 
with water prevents attachment from occurring far from the site of activation (207). The 
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association of the C4b2a complex with C3b forms a C5 convertase which initiates the terminal 
pathway. 
 The alternative pathway of activation proceeds without antibody binding and begins 
when the C3 complement protein is cleaved by the C3 convertase yielding two fragments: C3a 
and C3b. Low rates of cleavage occurs continuously in plasma resulting in constitutive activity 
and C3 binds to pathogen or host cell surfaces (208). The host, however, expresses several 
regulators, expressed predominantly on the cell surface, that suppress complement activation 
against self by downregulating central proteolytic activity (209). This pathway has been called 
‘reverse-recognition’ as it is based on the recognition of host-associated molecular patterns 
(HAMPs) rather than PAMPS. As microbes lack the HAMP regulators, predominantly sialic 
acid, the complement pathways proceeds (210).  A second plasma protein (factor B) can bind to 
C3b once it has attached to a cell surface. Factor B is then cleaved by a plasma serine protease 
(factor D) resulting in the C3bBb complex which functions as the alternative pathway C3 
convertase. C3 convertase increases the cleavage and activation of C3 molecules amplifiying the 
complement cascade (211; 212).  
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Figure A1. The steps of complement activation by the alternative, classical, or lectin pathways. 
Adapted from Abbas, Lichtman and Pillai (2012) (62) 
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The third pathway to complement activation, although similar to the classical pathway, is 
evolutionarily more ancient (213). It is triggered by mannose-binding lectin (MBL) and ficolins, 
plasma proteins which recognizes terminal mannose residues on microbial glycoproteins and 
glycolipids (214). Once MBL has bound to a microbe, two zymogens mannan-binding lectin 
associated serine protease (MASP1 and MASP2) are activated. MASP-2 cleaves both C4 and C2 
while MASP-1 plays a role in transactivating MASP-2 (215).  This initiates the same 
downstream proteolytic steps as in the classical and alternative pathways resulting in the 
cleavage of C5 into C5a and C5b by C5 convertase. C5b initiates the terminal pathway which 
leads to the assembly of the terminal components, C5,C6,C7,C8, and C9, which from the 
membrane attack complex (MAC). The MAC is a lipophilic complex which inserts itself in the 
bacterial cell membrane forming pores and ultimately residing in cell lysis (188). The 
complement system, however, does not play a major role in C. jejuni infection as rates of 
bacteraemia are very low and detected in < 1% of patients occurring most often in patients with a 
severely compromised immune system (15) 
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APPENDIX II: COLLABORATOR METHODOLODIES 
 
KatA expression and purification  
Overexpression of KatA (Fig. 1) was performed in E. coli BL21 cells using the protein 
expression vector pGST as described previously [26]. Briefly, the C. jejuni NCTC 11168 katA 
gene (Fig. 1) was PCR amplified using Pfx (Invitrogen, Burlington, ON) high fidelity 
polymerase and the KatA_NcoI (GCCATGGCTATGAAAAAATTGACTAACGA) and 
KatA_NotI (GCGGCCGCTTAGTTTGCCACCAAAAGTGG) primers (restriction site outlined 
in bold). The amplified gene was cloned into the protein overexpression vector pGST using NcoI 
and NotI restriction sites, to give rise to pGST+KatA construct which was transformed into E. 
coli BL21 cells. Sequencing was performed to confirm the absence of polymerase-introduced 
mutations in the katA gene. Once E. coli was cultured as mentioned above, the cells were then 
pelleted, resuspended in 100 mM NaCl, 20 mM Tris pH 7.3 buffer containing protease inhibitor 
(Roche, Mississauga, ON), and the cell membranes were disrupted by sonication. Cell 
membranes and debris were removed by centrifugation at 13000 rpm for 15 min. The cell lysate 
containing the GST-KatA fusion protein was then affinity purified using glutathione sepharose 
4B resin according to the manufacturer specifications (GE Healthcare, Baie d’Urfe, QC). 
Cleavage of the GST tag from KatA was performed on the resin by addition of TEV protease 
[26] and gentle shaking overnight at 4°C. The KatA protein was washed from the resin the 
following day using 100 mM NaCl, 20 mM Tris pH 7.3 buffer and concentrated using 30 kDa 
cut-off centrifugal filter unit (EMD Millipore, MA, USA). Concentrated KatA protein was 
further purified by size exclusion chromatography using the AKTA fast protein liquid 
chromatography (FPLC) system equipped with a Superdex-200 column (GE Healthcare) using 
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100 mM NaCl, 20 mM Tris pH 7.3 buffer as the filtration buffer and a flow rate of 0.4 mL/min. 
Purified protein was further concentrated to 2 mg/mL and stored at -20°C until use. 
Purification of KatA Antibodies from Sera 
Approximately 2.5 mg of KatA protein was used for antibody production by Immuno-Precise 
Antibodies Limited (Victoria, BC, Canada) using 2 rabbits. For each rabbit, a pre-immune bleed 
was performed prior to the primary immunization with the KatA antigen (0.5mg) using complete 
Freund’s antigen. Over the course of the project, each rabbit received 3 additional boosts with 
KatA antigen (0.5 mg) using incomplete Freund’s antigen followed by a terminal bleed and 
serum collection. Anti-KatA antiserum was stored at 20°C until use. 
Immunoprecipitation of KatA  
Immunoprecipitation experiments using wild-type C. jejuni, ΔCj1386, ΔkatA, and ΔCj1386 
ΔCj1386 strains were performed using protein A-conjugated Dynabeads (Invitrogen). Strains 
were grown to mid-log phase (OD600 of 0.2) in MEM under microaerophilic conditions at 37°C 
prior to harvesting total soluble pro teins. Bacterial strains were spun at 6,000 rpm for 10 min, 
resuspended in 1ml PBS containing a bacterial protease inhibitor cocktail (Sigma) and 10 mg/ml 
lysozyme, and incubated on ice for 15 min. Cells were briefly sonicated once (five 5 pulses), 
followed by centrifugation at 13,000 rpm for 5 min at 4°C to remove membranes and cellular 
debris. Two hundred and fifty micrograms of anti-KatA antiserum diluted in 200 µl PBS-0.02%  
Tween 20 was incubated with 50 µl of Dynabeads for 1 h with end-over-end rotation at room 
temperature. The anti-KatA-bound Dynabeads were washed once with 500 µl PBS-0.02% Tween 
20 before addition of 5 mg of protein lysate. The bead-lysate mixture was incubated overnight at 
4°C with end-over-end rotation. The beads were washed 3 times with 200 µl of ice-chilled PBS, 
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and KatA was eluted from the beads twice in 100 µl soft-elution buffer (50 mM Tris, pH 8.0, 
0.2% SDS, 0.1% Tween 20) with end-over-end rotation for 7 min at room temperature. 
Immunoprecipitation of KatA from each strain was visualized by SDS-PAGE run on a 10% 
denaturing gel followed by Coomassie blue staining. KatA protein concentration was determined 
for each immunoprecipitated sample by densitometry of the SDS-PAGE gel using Adobe Photo 
shop software (version 10.0). KatA protein content was normalized, and equal amounts of KatA 
(250 ng) from the wild-type NCTC11168, ΔCj1386, and ΔCj1386 ΔCj1386 strains were assayed 
for catalase activity using the method described above. Immunoprecipitate from the ΔKatA strain 
was used as a negative control for the catalase activity assay. Catalase activity assays were 
performed in quadruplicate, and statistical significance was determined using the Student t-test. P 
values of <0.05 were considered significant. 
Proteomics 
Proteomics analysis was performed at the OHRI Proteomics Core Facility (Ottawa, Canada).   
Protein Digest 
Proteins were digested in-gel using trypsin (Promega) according to the method of Shevchenko 
(Nat Protocols 2006; 1(6):2856-60).  The resulting peptide extracts were concentrated by 
vacufuge (Eppendorf) and resuspended in 0.1% formic acid (Fisher). 
LC-MS/MS 
Peptides were analyzed by LC-MS/MS (liquid chromatography – tandem mass spectrometry) on 
a system comprised of an UltiMate 3000 RSLC nano HPLC, LTQ Orbitrap XL hybrid mass 
spectrometer and nanospray ionization source (Thermo Scientific).  The system was controlled 
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by Xcalibur software version 2.0.7 (Thermo Scientific). Peptides were loaded by autosampler 
onto a C18 CapTrap (Michrom) in 3% acetonitrile, 0.1% formic acid at a flow rate of 15 
microlitres per minute for 5 minutes.   Peptides were eluted over a 60 minute gradient of 3% - 
45% acetonitrile at a flow rate of 300 nanolitres per minute through a 10-cm long column with 
integrated emitter tip (Picofrit PF360-75-15-N-5 from New Objective packed with Zorbax SB-
C18, 5 micron from Agilent), and nanosprayed into the mass spectrometer.  Nanoflow HPLC 
solvents contained 0.1% formic acid and 5% DMSO (Nature Methods 2013; 10(10):989). MS 
scans were acquired in FTMS mode at a resolution setting of 60,000.  MS2 scans were acquired 
in ion trap CID mode using data-dependent acquisition of the top 5 ions from each MS scan. 
Protein Identification Using Mascot 
MASCOT software version 2.4 (Matrix Science, UK) was used to infer peptide and protein 
identities from the mass spectra.  The observed MS/MS spectra were matched against C. jejuni 
sequences from SwissProt version 2013_05 and also against a database of common 
contaminants.  Mass tolerance parameters were MS ±10 ppm and MS/MS ±0.6 Da.  Enzyme 
specificity was set to ‘Trypsin’ with <=2 miscuts.  Oxidation of methionine, protein N-terminal 
acetylation, and conversion of glutamine to pyro-glutamate were allowed as variable 
modifications. Carbamidomethylation of cysteine was set as a fixed modification. 
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